Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
2018; Massachusetts Medical Society; Volume: 378; Issue: 18 Linguagem: Inglês
10.1056/nejmoa1706441
ISSN1533-4406
AutoresMichael Egan, James Kost, Pierre N. Tariot, Paul Aisen, Jeffrey L. Cummings, Bruno Vellas, Cyrille Sur, Yuki Mukai, Tiffini Voss, Christine Furtek, Erin Mahoney, Lyn Harper Mozley, Rik Vandenberghe, Mo Yi, David Michelson,
Tópico(s)Cholinesterase and Neurodegenerative Diseases
ResumoAlzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) followed by γ-secretase. Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease.
Referência(s)